BMS-986315 is an experimental immunotherapy drug that works targetting a molecule called NKG2A. This may allow the body to mount a more robust anti-cancer immune response.
This drug will be tested alone, as well as in combination with one of two Health Canada-approved anti-cancer therapies: Nivolumab (Opdivo®) and Cetuximab (Erbitux®).
Nivolumab is already approved for the treatment of Kidney Cancer and targets a molecule called PD-1. Blocking PD-1 helps to prime the body’s immune defences in order to target and destroy cancer cells.
Cetuximab is not yet used to treat Kidney Cancer but is approved for a number of other cancers. It works by blocking a molecule called EGFR which helps cells grow and divide, thus slowing cancer growth.
This study will have three treatment groups that will be assigned by the doctor overseeing your care.
Group 1: BMS-986315 alone
Group 2: BMS-986315 with Nivolumab
Group 3: BMS-986315 with Cetuximab
In order to maximize effectiveness and minimize side effects, different doses of each drug may be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive treatment.
- All subtypes eligible
- Advanced kidney cancer that cannot be removed by surgery
- No further drug treatments are available or recommended
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBristol-Myers Squibb Research Centre||Principal InvestigatorBristol-Myers Squibb - Site 0014||LocationEdmonton, AB||Trial StatusNot yet recruiting|
|Hospital / Cancer CentreBristol-Myers Squibb Research Centre||Principal InvestigatorBristol-Myers Squibb - Site 0004||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreBristol-Myers Squibb Research Centre||Principal InvestigatorBristol-Myers Squibb - Site 0005||LocationMontreal, QC||Trial StatusRecruiting|